Display options
Cite
Jin J, Choi SH, Lee JE, et al. Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. Oncol Lett. 2017;13(5):3767-3773doi: 10.3892/ol.2017.5918.
Jin, J., Choi, S. H., Lee, J. E., Joo, J. D., Han, J. H., Park, S. Y., & Kim, C. Y. (2017). Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. Oncology letters, 13(5), 3767-3773. https://doi.org/10.3892/ol.2017.5918
Jin, Jun, et al. "Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model." Oncology letters vol. 13,5 (2017): 3767-3773. doi: https://doi.org/10.3892/ol.2017.5918
Jin J, Choi SH, Lee JE, Joo JD, Han JH, Park SY, Kim CY. Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. Oncol Lett. 2017 May;13(5):3767-3773. doi: 10.3892/ol.2017.5918. Epub 2017 Mar 27. PMID: 28529591; PMCID: PMC5431494.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 May;13(5):3767-3773. doi: 10.3892/ol.2017.5918. Epub 2017 Mar 27.

Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model.

Oncology letters

Jun Jin, Suh Hee Choi, Jung Eun Lee, Jin-Deok Joo, Jung Ho Han, Su-Young Park, Chae-Yong Kim

Affiliations

  1. Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 13620, Republic of Korea.
  2. Department of Neurosurgery, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  3. Research and Development Center, Daewoo Pharmaceutical Ind. Co., Ltd., Busan 49393, Republic of Korea.

PMID: 28529591 PMCID: PMC5431494 DOI: 10.3892/ol.2017.5918

Abstract

Chemoradiotherapy with temozolomide is the current standard treatment option for patients with glioblastoma. However, the majority of patients with glioblastoma survive for <2 years. Therefore, it is necessary to develop more effective therapeutic strategies for the treatment of glioblastoma. 7-O-succinyl macrolactin A tromethamine salt (SMA salt), a macrolactin compound, is known to possess an antiangiogenic activity. The present study investigated the antitumor effects of SMA salt in the treatment of glioblastoma by evaluating

Keywords: 7-O-succinyl macrolactin A tromethamine salt; glioblastoma; invasion; macrolactin A; migration

References

  1. N Engl J Med. 2014 Feb 20;370(8):699-708 - PubMed
  2. Antimicrob Agents Chemother. 2014 Sep;58(9):5036-46 - PubMed
  3. Neuro Oncol. 2002 Oct;4(4):261-7 - PubMed
  4. EMBO J. 1991 Dec;10(13):4025-31 - PubMed
  5. J Neurooncol. 2012 Jan;106(1):147-53 - PubMed
  6. Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 - PubMed
  7. Lancet Oncol. 2014 Sep;15(10 ):1100-8 - PubMed
  8. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 - PubMed
  9. J Neurosurg. 2011 Mar;114(3):663-9 - PubMed
  10. Arch Pharm Res. 2011 Jan;34(1):147-52 - PubMed
  11. J Clin Oncol. 2008 Dec 1;26(34):5610-7 - PubMed
  12. Clin Cancer Res. 2004 Feb 15;10(4):1255-62 - PubMed
  13. J Neurosurg. 1995 Oct;83(4):665-71 - PubMed
  14. J Neurooncol. 2008 May;88(1):43-50 - PubMed
  15. Arch Pharm Res. 2015 Feb;38(2):249-60 - PubMed
  16. Expert Rev Anticancer Ther. 2001 Oct;1(3):395-401 - PubMed
  17. N Engl J Med. 2014 Feb 20;370(8):709-22 - PubMed
  18. Int J Cancer. 2013 Aug 1;133(3):749-56 - PubMed
  19. Neurosurgery. 2002 Mar;50(3):599-605; discussion 605-6 - PubMed
  20. Neurosurgery. 1990 Apr;26(4):622-8 - PubMed
  21. Eur J Pharmacol. 2014 Jul 15;735:184-92 - PubMed
  22. Clin Cancer Res. 2000 Mar;6(3):971-8 - PubMed
  23. J Neurooncol. 2004 Jul;68(3):207-15 - PubMed
  24. Cancer. 2012 Nov 15;118(22):5601-7 - PubMed
  25. Neurotherapeutics. 2009 Jul;6(3):447-57 - PubMed
  26. J Clin Oncol. 2007 May 1;25(13):1651-7 - PubMed
  27. J Neurooncol. 2007 Nov;85(2):133-48 - PubMed
  28. J Clin Oncol. 2010 Jun 1;28(16):2712-8 - PubMed
  29. Brain Pathol. 2009 Oct;19(4):674-93 - PubMed
  30. Recent Pat Anticancer Drug Discov. 2010 Nov;5(3):172-87 - PubMed
  31. Cancer Res. 1998 Oct 15;58(20):4654-9 - PubMed
  32. Am J Pathol. 2010 Sep;177(3):1491-502 - PubMed
  33. Neoplasia. 2005 Jan;7(1):48-56 - PubMed
  34. Antimicrob Agents Chemother. 2006 May;50(5):1701-9 - PubMed
  35. N Engl J Med. 2005 Mar 10;352(10 ):997-1003 - PubMed
  36. Cancer Gene Ther. 2005 Mar;12(3):284-94 - PubMed
  37. PLoS One. 2015 Nov 06;10(11):e0141753 - PubMed
  38. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  39. Mol Oncol. 2010 Oct;4(5):420-30 - PubMed

Publication Types